Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Profile Name NTRK1 fusion
Gene Variant Detail

NTRK1 fusion (unknown)

Relevant Treatment Approaches Trk Receptor Inhibitor (Pan)

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
NTRK1 fusion skin melanoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) therapy is included in guidelines for patients with metastatic or unresectable cutaneous melanoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion ovarian cancer sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as systemic therapy for patients with recurrent ovarian cancer harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion Erdheim-Chester disease sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as first-line or subsequent-line therapy for patients with Erdheim-Chester disease harboring NTRK1 fusions (NCCN.org). detail...
NTRK1 fusion vulva squamous cell carcinoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with advanced or metastatic vulvar squamous cell carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion esophageal cancer sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as second-line or subsequent therapy for patients with advanced or metastatic esophageal cancer with an NTRK fusion (NCCN.org). detail...
NTRK1 fusion pancreatic adenocarcinoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is in guidelines as second-line therapy for patients with advanced or metastatic pancreatic adenocarcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion thyroid gland papillary carcinoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with papillary thyroid carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion lung non-small cell carcinoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Phase I Actionable In a Phase I clinical trial, Rozlytrek (entrectinib) treatment resulted in partial response for more than 6 months and complete resolution of brain metastases in a non-small cell lung carcinoma patient harboring a SQSTM1-NTRK1 gene fusion (PMID: 26565381). 26565381
NTRK1 fusion lung non-small cell carcinoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as first-line or subsequent therapy for patients with advanced or metastatic non-small cell lung cancer harboring an NTRK1 fusion (NCCN.org). detail...
NTRK1 fusion rectum cancer sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines for advanced or metastatic rectal cancer patients with an NTRK fusion (NCCN.org). detail...
NTRK1 fusion lung cancer predicted - sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Phase II Actionable In a combined analysis of two clinical trials, Vitrakvi (larotrectinib) treatment demonstrated safety and resulted in an objective response rate (ORR) of 73% (11/15, 1 complete response, 10 partial responses) in 15 evaluable lung cancer patients of 20 harboring NTRK1 (n=16) or NTRK3 (n=4) fusions, with median progression-free survival (PFS) of 35.4 mo, a 12-mo PFS rate of 65%, and 33.9 mo duration of response, and ORR in patients with CNS metastasis was 63% (5/8) (PMID: 35085007; NCT02122913, NCT02576431). 35085007
NTRK1 fusion Advanced Solid Tumor sensitive Trk Receptor Inhibitor (Pan) Entrectinib FDA approved Actionable In a combined analysis of 3 clinical trials (ALKA-372-001, STARTRK-1, STARTRK-2) that supported FDA approval, Rozlytrek (entrectinib) treatment resulted in an objective response rate of 57% (31/54, 4 complete response, 27 partial response) in patients with NTRK1/2/3 fusion-positive advanced solid tumors, with a median duration of response of 10 months (PMID: 31838007; 2012-000148-88, NCT02097810, NCT02568267). detail... 31838007
NTRK1 fusion Advanced Solid Tumor sensitive Trk Receptor Inhibitor (Pan) Entrectinib Case Reports/Case Series Actionable In a Phase I/II trial (STARTRK-NG), Rozlytrek (entrectinib) treatment was safe and resulted in an overall response rate (ORR) of 57.7% (15/26, 7 complete responses) with median duration of response and progression-free survival no reached in pediatric patients with CNS or extracranial solid tumors harboring fusions in NTRK1, NTRK2, NTRK3, ROS1, or ALK, ORR was 60% (9/15) in patients harboring fusions in NTRK1/2/3 (PMID: 35395680; NCT02650401). 35395680
NTRK1 fusion vulva squamous cell carcinoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines for patients with advanced or metastatic vulva squamous cell carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion endometrial carcinoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as a second-line therapy for patients with endometrial carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion hepatocellular carcinoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines as subsequent-line therapy for patients with hepatocellular carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion colorectal cancer sensitive Trk Receptor Inhibitor (Pan) AZD7451 Preclinical Actionable In a preclinical study, AZD7451 treatment efficiently inhibited proliferation of a colorectal cancer cell line harboring a NTRK1 fusion in culture (PMID: 25054037). 25054037
NTRK1 fusion Advanced Solid Tumor sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Phase Ib/II Actionable In a Phase I/II trial (SCOUT), Vitrakvi (larotrectinib) treatment resulted in complete response in 26.7% (4/15), partial response in 66.7% (10/15), and stable disease in 6.7% (1/15) of pediatric patients with advanced solid tumors harboring NTRK fusions, and progressive diseases in all 7 patients without NTRK fusions (PMID: 29606586; NCT02637687). 29606586
NTRK1 fusion Advanced Solid Tumor sensitive Trk Receptor Inhibitor (Pan) Larotrectinib FDA approved Actionable In three trials that supported FDA approval, Vitrakvi (larotrectinib) treatment resulted in an overall response rate of 75% (41/55) in adult and pediatric patients with advanced solid tumors harboring either an NTRK1, NTRK2, or NTRK3 fusion, including 7 patients achieving a complete response and 34 patients achieving a partial response (PMID: 29466156; NCT02122913, NCT02637687, NCT02576431). detail... 29466156 detail...
NTRK1 fusion gastroesophageal junction adenocarcinoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines as second-line or subsequent therapy for patients with advanced or metastatic gastroesophageal junction cancer with an NTRK fusion (NCCN.org). detail...
NTRK1 fusion thyroid gland anaplastic carcinoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with metastatic thyroid gland anaplastic carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion anaplastic astrocytoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines for patients with recurrent anaplastic gliomas harboring an NTRK fusion, including anaplastic astrocytoma (NCCN.org). detail...
NTRK1 fusion gallbladder cancer sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines as primary therapy for patients with unresectable or metastatic gallbladder cancer harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion thyroid gland follicular carcinoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines for patients with follicular thyroid carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion intrahepatic cholangiocarcinoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines as primary therapy for patients with unresectable or metastatic intrahepatic cholangiocarcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion central nervous system cancer sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Phase II Actionable In two Phase II trials, Vitrakvi (larotrectinib) treatment resulted in an objective response rate of 30% (10/33, 3 complete responses, 7 partial responses) in pediatric and adult patients with primary central nervous system tumors harboring NTRK fusions including high grade (n=19) and low grade (n=8) gliomas, with a 24-week disease control rate of 73% and a 12-month progression-free survival rate of 56% (PMID: 34850167; NCT02637687, NCT02576431). 34850167
NTRK1 fusion colon cancer sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for advanced or metastatic colon cancer patients with an NTRK fusion (NCCN.org). detail...
NTRK1 fusion ampulla of Vater adenocarcinoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines as first-line therapy when the performance score is poor or as subsequent therapy for metastatic ampullary adenocarcinoma patients harboring NTRK fusions (NCCN.org). detail...
NTRK1 fusion cholangiocarcinoma predicted - sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Phase I Actionable In a Phase I trial, Vitrakvi (larotrectinib) treatment resulted in partial response in a patient with cholangiocarcinoma harboring NTRK1 fusion (Annals of Oncology, Volume 29, Issue suppl_5; NCT02122913, NCT02637687, and NCT02576431). detail...
NTRK1 fusion salivary gland cancer sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with NTRK1 fusion-positive salivary gland tumors with distant metastasis (NCCN.org). detail...
NTRK1 fusion breast cancer sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) therapy is included in guidelines for patients with recurrent or metastatic breast cancer harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion Advanced Solid Tumor predicted - sensitive Trk Receptor Inhibitor (Pan) ICP-723 Case Reports/Case Series Actionable In a Phase I trial, ICP-723 treatment was well tolerated and resulted in an overall response rate of 66.7% (4/6, all partial responses) and a disease control rate of 100% (6/6) in patients with NTRK fusion-positive advanced solid tumors, including one partial response with a measurable decrease in the brain lesion (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 3106; NCT04685226). detail...
NTRK1 fusion thyroid gland Hurthle cell carcinoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with thyroid Hurthle cell carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion appendix cancer predicted - sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Case Reports/Case Series Actionable In a Phase I trial, Vitrakvi (larotrectinib) treatment resulted in stable disease in a patient with appendix cancer harboring NTRK1 fusions (PMID: 29466156, Annals of Oncology, Volume 29, Issue suppl_5; NCT02122913, NCT02637687, and NCT02576431). 29466156 detail...
NTRK1 fusion glioblastoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with recurrent glioblastoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion gastrointestinal stromal tumor sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines for patients with advanced/metastatic gastrointestinal stromal tumor (GIST) harboring NTRK fusions (PMID: 34560242; ESMO.org). detail... 34560242
NTRK1 fusion gastrointestinal stromal tumor sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines for patients with unresectable gastrointestinal stromal tumor (GIST) harboring NTRK fusions (NCCN.org). detail...
NTRK1 fusion gastroesophageal junction adenocarcinoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as second-line or subsequent therapy for patients with advanced or metastatic gastroesophageal junction cancer with an NTRK fusion (NCCN.org). detail...
NTRK1 fusion pancreatic adenocarcinoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with advanced or metastatic pancreatic adenocarcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion gastrointestinal system cancer predicted - sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Phase I Actionable In a Phase I trial, Vitrakvi (larotrectinib) treatment resulted in an objective response rate of 75% (8/12, 1 complete response, 7 partial responses) in patients with gastrointestinal system malignancies harboring NTRK fusions, including colon cancer, pancreatic carcinoma, cholangiocarcinoma and GIST, and stable disease in 3 patients, with duration of response ranging from 3.5 to 22.9 months (Annals of Oncology, Volume 29, Issue suppl_5; NCT02122913, NCT02637687, and NCT02576431). detail...
NTRK1 fusion cervical cancer sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines as second-line therapy for patients with recurrent or metastatic cervical cancer harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion differentiated thyroid gland carcinoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines for adult or pediatric patients 12 years or older with metastatic differentiated thyroid gland carcinoma harboring NTRK fusions that have progressed on prior therapies (PMID: 31549998, PMID: 35491008; ESMO.org). 35491008 31549998 detail...
NTRK1 fusion glioblastoma predicted - sensitive Trk Receptor Inhibitor (Pan) Carboplatin + Etoposide + Larotrectinib Case Reports/Case Series Actionable In a clinical case study, Vitrakvi (larotrectinib), Paraplatin (carboplatin), and Vepesid (etoposide) combination treatment resulted in complete tumor regression after 8 weeks in a pediatric patient with congenital spinal cord glioblastoma harboring an NTRK1 fusion, who remained tumor-free at 17 months (PMID: 34895532). 34895532
NTRK1 fusion cervical cancer sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as second-line therapy for patients with recurrent or metastatic cervical cancer harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion thyroid gland cancer predicted - sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Phase II Actionable In a combined analysis of two clinical trials, Vitrakvi (larotrectinib) treatment demonstrated a favorable safety profile, resulted in an objective response rate of 75% (21/28, 2 complete responses, 19 partial responses) in patients with non-medullary, advanced thyroid cancer harboring NTRK1 (n=12) or NTRK3 (n=16) fusions, with median progression-free survival (PFS) not reached and a 12-month PFS rate of 81% (Annals of Oncology (2020) 31 (suppl_4): S1086; NCT02122913, NCT02576431). detail...
NTRK1 fusion endometrial carcinoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines as a second-line therapy for patients with endometrial carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion Advanced Solid Tumor predicted - sensitive Trk Receptor Inhibitor (Pan) Selitrectinib Phase I Actionable In a Phase I trial, Selitrectinib (LOXO-195) treatment resulted in an objective response rate of 34% (10/29) and stable disease in 31% (9/29) of adult and pediatric patients with advanced solid tumors harboring NTRK fusions and had progressed or were intolerant to prior Trk inhibitors (AACR Annual Meeting 2019, Abstract CT127; NCT03215511). detail...
NTRK1 fusion thyroid gland papillary carcinoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines for patients with papillary thyroid carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion anaplastic astrocytoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with recurrent anaplastic gliomas harboring an NTRK fusion, including anaplastic astrocytoma (NCCN.org). detail...
NTRK1 fusion pancreatic cancer predicted - sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Case Reports/Case Series Actionable In a Phase I trial, Vitrakvi (larotrectinib) treatment resulted in partial response in a patient with pancreatic cancer harboring NTRK1 fusions (PMID: 29466156, Annals of Oncology, Volume 29, Issue suppl_5; NCT02122913, NCT02637687, and NCT02576431). 29466156 detail...
NTRK1 fusion ampulla of Vater adenocarcinoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as first-line therapy when the performance score is poor or as subsequent therapy for metastatic ampullary adenocarcinoma patients harboring NTRK fusions (NCCN.org). detail...
NTRK1 fusion thyroid gland anaplastic carcinoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines for patients with metastatic thyroid gland anaplastic carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion small intestine adenocarcinoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as a subsequent-line therapy for patients with advanced or metastatic small bowel adenocarcinoma with an NTRK fusion and no satisfactory alternative treatments (NCCN.org). detail...
NTRK1 fusion colon cancer sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Case Reports/Case Series Actionable In a Phase I trial, Vitrakvi (larotrectinib) treatment resulted in partial response in 50% (2/4) and stable disease in 50% (2/4) of patients with colon cancer harboring NTRK1 fusions (PMID: 29466156, Annals of Oncology, Volume 29, Issue suppl_5; NCT02122913, NCT02637687, and NCT02576431). 29466156 detail...
NTRK1 fusion colon cancer sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines for advanced or metastatic colon cancer patients with an NTRK fusion (NCCN.org). detail...
NTRK1 fusion thyroid gland Hurthle cell carcinoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines for patients with thyroid Hurthle cell carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion rectum cancer sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for advanced or metastatic rectal cancer patients with an NTRK fusion (NCCN.org). detail...
NTRK1 fusion low grade glioma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines for patients with recurrent or progressive low grade glioma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion stomach cancer sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as second-line or subsequent therapy for patients with advanced or metastatic gastric cancer with an NTRK fusion (NCCN.org). detail...
NTRK1 fusion small intestine adenocarcinoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines as a subsequent-line therapy for patients with advanced or metastatic small bowel adenocarcinoma with an NTRK fusion and no satisfactory alternative treatments (NCCN.org). detail...
NTRK1 fusion stomach cancer sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines as second-line or subsequent therapy for patients with advanced or metastatic gastric cancer with an NTRK fusion (NCCN.org). detail...
NTRK1 fusion gastrointestinal stromal tumor sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with unresectable gastrointestinal stromal tumor (GIST) harboring NTRK fusions (NCCN.org). detail...
NTRK1 fusion gastrointestinal stromal tumor sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with advanced/metastatic gastrointestinal stromal tumor (GIST) harboring NTRK fusions (PMID: 34560242; ESMO.org). detail... 34560242
NTRK1 fusion Erdheim-Chester disease sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines as first-line or subsequent-line therapy for patients with Erdheim-Chester disease harboring NTRK1 fusions (NCCN.org). detail...
NTRK1 fusion sarcoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is in guidelines for patients with soft tissue sarcoma with non-specific histology and an NTRK fusion (NCCN.org). detail...
NTRK1 fusion uterine corpus sarcoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with uterine sarcoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion esophageal cancer sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines as second-line or subsequent therapy for patients with advanced or metastatic esophageal cancer with an NTRK fusion (NCCN.org). detail...
NTRK1 fusion hepatocellular carcinoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as subsequent-line therapy for patients with hepatocellular carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion breast cancer sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) therapy is included in guidelines for patients with recurrent or metastatic breast cancer harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion anaplastic oligodendroglioma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with recurrent anaplastic gliomas harboring an NTRK fusion, including anaplastic oligodendroglioma (NCCN.org). detail...
NTRK1 fusion sarcoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is in guidelines for patients with soft tissue sarcoma with non-specific histology and an NTRK fusion (NCCN.org). detail...
NTRK1 fusion anaplastic oligodendroglioma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines for patients with recurrent anaplastic gliomas harboring an NTRK fusion, including anaplastic oligodendroglioma (NCCN.org). detail...
NTRK1 fusion extrahepatic bile duct carcinoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines as primary therapy for patients with unresectable or metastatic extrahepatic cholangiocarcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion uterine corpus sarcoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines for patients with uterine sarcoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion differentiated thyroid gland carcinoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for adult or pediatric patients 12 years or older with metastatic or unresectable differentiated thyroid gland carcinoma harboring NTRK fusions that have progressed on prior therapies (PMID: 31549998, PMID: 35491008; ESMO.org). detail... 35491008 31549998
NTRK1 fusion extrahepatic bile duct carcinoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as primary therapy for patients with unresectable or metastatic extrahepatic cholangiocarcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion intrahepatic cholangiocarcinoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as primary therapy for patients with unresectable or metastatic intrahepatic cholangiocarcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion salivary gland cancer sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines for patients with NTRK1 fusion-positive salivary gland tumors with distant metastases (NCCN.org). detail...
NTRK1 fusion glioblastoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines for patients with recurrent glioblastoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion gallbladder cancer sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines as primary therapy for patients with unresectable or metastatic gallbladder cancer harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion Advanced Solid Tumor predicted - sensitive Trk Receptor Inhibitor (Pan) Repotrectinib Phase I Actionable In a Phase I (TRIDENT-1) trial, Repotrectinib (TPX-0005) treatment resulted in partial response in 21.6% (8/37) of patients with advanced solid tumors harboring ROS1 or NTRK fusions (J Clin Oncol 36, 2018 (suppl; abstr 2513); NCT03093116). detail...
NTRK1 fusion thyroid gland follicular carcinoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with follicular thyroid carcinoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion skin melanoma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) therapy is included in guidelines for patients with metastatic or unresectable cutaneous melanoma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion ovarian cancer sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is included in guidelines as systemic therapy for patients with recurrent ovarian cancer harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion low grade glioma sensitive Trk Receptor Inhibitor (Pan) Entrectinib Guideline Actionable Rozlytrek (entrectinib) is included in guidelines for patients with recurrent or progressive low grade glioma harboring an NTRK fusion (NCCN.org). detail...
NTRK1 fusion lung non-small cell carcinoma sensitive Trk Receptor Inhibitor (Pan) Larotrectinib Guideline Actionable Vitrakvi (larotrectinib) is in guidelines as first-line therapy for patients with metastatic non-small cell lung cancer harboring an NTRK fusion (NCCN.org). detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04484142 Phase II Datopotamab Deruxtecan Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) Active, not recruiting USA | ITA | FRA | ESP | DEU 5
NCT04862780 Phase Ib/II BLU-945 Study Targeting EGFR Resistance Mechanisms in NSCLC Recruiting USA | ESP 7
NCT04265534 Phase II Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium + Telaglenastat Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE) Terminated USA 0
NCT04901806 Phase Ib/II PBI-200 Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors Recruiting USA 2
NCT05435846 Phase I Capmatinib + Trametinib Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation Recruiting USA 0
NCT05153408 Phase Ib/II BLU-701 BLU-701 + Osimertinib BLU-701 + Carboplatin + Pemetrexed Disodium (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC Recruiting USA 0
NCT03834961 Phase II Larotrectinib Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia Recruiting USA | CAN 0
NCT02650401 Phase I Entrectinib Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG) Recruiting USA | ITA | FRA | ESP | DEU | CAN 5
NCT03827850 Phase II Erdafitinib FGFR Inhibitor in FGFR Dysregulated Cancer (FIND) Recruiting DEU 0
NCT05200481 Phase II Brigatinib + Carboplatin + Pemetrexed Disodium Brigatinib Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) Recruiting FRA 0
NCT02587650 Phase II Ceritinib Capmatinib Regorafenib Entrectinib Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma Terminated USA 0
NCT01639508 Phase II Cabozantinib Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity Recruiting USA 0
NCT05241873 Phase Ib/II BLU-451 Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations Recruiting USA 0
NCT04270591 Phase Ib/II SCC244 Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer Recruiting USA 2
NCT05064280 Phase II Lenvatinib Pembrolizumab Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases Recruiting USA 0
NCT02122913 Phase I Larotrectinib A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer Completed USA 0
NCT02465060 Phase II Erdafitinib Trametinib Crizotinib Sapanisertib AZD4547 Dasatinib Osimertinib Palbociclib Capivasertib Larotrectinib Ulixertinib Nivolumab + Relatlimab Copanlisib Sunitinib Nivolumab Pertuzumab + Trastuzumab Ipatasertib Dabrafenib + Trametinib Binimetinib Adavosertib Afatinib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Taselisib Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Recruiting USA 2
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting USA 1
NCT03215511 Phase Ib/II Selitrectinib A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer Active, not recruiting USA | ITA | FRA | ESP | DEU | BEL 4
NCT01804530 Phase I PLX7486 Gemcitabine + Nab-paclitaxel Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors Terminated USA 0
NCT02637687 Phase I Larotrectinib A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT) Recruiting USA | ITA | FRA | ESP | DEU | CAN 16
NCT03213704 Phase II Larotrectinib Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Recruiting USA 1
NCT03066661 Expanded access Entrectinib Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions No longer available USA 0
NCT03520686 Phase III ALT-803 + Carboplatin + Pembrolizumab + Pemetrexed Disodium ALT-803 + Cisplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab ALT-803 + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium ALT-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC. Recruiting USA 0
NCT04581824 Phase II Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Dostarlimab-gxly + Pemetrexed Disodium Carboplatin + Dostarlimab-gxly + Pemetrexed Disodium Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Active, not recruiting USA | ITA | FRA | ESP | DEU 7
NCT04655404 Phase I Larotrectinib A Pilot Study of Larotectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion (CONNECT1903) Recruiting USA | DEU | CAN 3
NCT05215340 Phase III Pembrolizumab Datopotamab Deruxtecan + Pembrolizumab Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08) Recruiting USA | ESP 7
NCT05004116 Phase Ib/II Irinotecan + Repotrectinib + Temozolomide A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer Recruiting USA 0
NCT04656652 Phase III Docetaxel Datopotamab Deruxtecan Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 19
NCT04827576 Phase II Docetaxel + Hu5F9-G4 Study of Magrolimab in Participants With Solid Tumors Recruiting USA | FRA | ESP 1
NCT04995523 Phase Ib/II AZD2936 A Study to Assess the Safety and Efficacy of AZD2936 in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (ARTEMIDE-01) Recruiting USA | FRA | ESP | BEL 9
NCT05313009 Phase Ib/II Sotorasib + TH-4000 Tarlox and Sotorasib in Patients With KRAS G12C Mutations Recruiting USA 0
NCT03953235 Phase Ib/II GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens Recruiting USA 0
NCT04526691 Phase I Cisplatin + Datopotamab Deruxtecan + Pembrolizumab Carboplatin + Datopotamab Deruxtecan + Pembrolizumab Datopotamab Deruxtecan + Pembrolizumab Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) Recruiting USA | ITA | ESP 2
NCT04612751 Phase I Datopotamab Deruxtecan + Durvalumab Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab With or Without Carboplatin in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04) Recruiting USA | FRA | BEL 1
NCT03639714 Phase Ib/II GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab A Study of a Personalized Neoantigen Cancer Vaccine Active, not recruiting USA 1
NCT02097810 Phase I Entrectinib Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1) Completed USA 1
NCT02576431 Phase II Larotrectinib A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 24
NCT05117242 Phase II GEN1046 + Pembrolizumab GEN1046 Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer Recruiting USA | ESP 2
NCT04923126 Phase Ib/II PD-0325901 SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma Recruiting USA 0
NCT04083976 Phase II Erdafitinib A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 11
NCT04467801 Phase II Ipatasertib Docetaxel + Ipatasertib Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy Recruiting USA 0
NCT03556228 Phase I VMD-928 Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Recruiting USA 0
NCT04655976 Phase II Docetaxel Cobolimab + Docetaxel + Dostarlimab-gxly Docetaxel + Dostarlimab-gxly Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants (COSTAR Lung) Recruiting USA | ITA | FRA | ESP | DEU | CAN 11
NCT04589845 Phase II Alectinib Ado-trastuzumab emtansine Ipatasertib GDC-0077 Entrectinib Atezolizumab Idasanutlin Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Recruiting USA | ITA | FRA | ESP | DEU | CAN | BEL 18
NCT05077800 Phase II 9-ING-41 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin 9-ING-41 + Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer Recruiting USA 0
NCT03994796 Phase II Abemaciclib GDC-0084 Entrectinib Genetic Testing in Guiding Treatment for Patients With Brain Metastases Recruiting USA 0
NCT04302025 Phase II Cobimetinib + Vemurafenib Entrectinib Atezolizumab Alectinib Pralsetinib A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer Recruiting USA 0
NCT04094610 Phase Ib/II Repotrectinib A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Recruiting USA | CAN 4
NCT04116541 Phase II Alectinib Cabozantinib Ribociclib + Siremadlin A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST) Recruiting FRA 0